The United States Patent and Trademark Office (USPTO) has issued US Patent No. 7,994,197, titled “Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine while Minimizing Side Effect Profile,” to MAP Pharmaceuticals for its Levadex inhaled dihydroergotamine (DHE) technology. The patent will expire in 2028.
“We have designed LEVADEX to overcome the limitations of currently available migraine therapies by combining our novel formulation capabilities with our proprietary TEMPO inhaler, and to target an optimal pharmacokinetic profile for rapid relief of migraine while minimizing side effects. The issuance of this patent strengthens MAP Pharmaceuticals’ patent estate relating to our LEVADEX product candidate,” commented Timothy S. Nelson, MAP’s President and CEO.
The US FDA recently accepted MAP’s NDA for Levadex, and the company recently created the position of Vice President, Commercial Operations to head the anticipated product launch.
Read the MAP Pharmaceuticals press release.
